- Home
- Publications
- Publication Search
- Publication Details
Title
Intravitreal anti-VEGF agents and cardiovascular risk
Authors
Keywords
-
Journal
Internal and Emergency Medicine
Volume 15, Issue 2, Pages 199-210
Publisher
Springer Science and Business Media LLC
Online
2019-12-17
DOI
10.1007/s11739-019-02253-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Association of Intravitreal Anti–Vascular Endothelial Growth Factor Therapy With Risk of Stroke, Myocardial Infarction, and Death in Patients With Exudative Age-Related Macular Degeneration
- (2019) Lauren A. Dalvin et al. JAMA Ophthalmology
- Classification of Strokes in Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor
- (2019) Matthew R. Starr et al. Ophthalmic Surgery Lasers & Imaging Retina
- Eye complications of diabetes
- (2019) Giuseppe Querques ACTA DIABETOLOGICA
- Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an update
- (2019) Ciro Costagliola et al. Expert Opinion On Drug Safety
- Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results
- (2019) Catharina Busch et al. ACTA DIABETOLOGICA
- Influence of aflibercept on platelet activation profile
- (2018) B. Sobolewska et al. EXPERIMENTAL EYE RESEARCH
- Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti–Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema
- (2018) Lee M. Jampol et al. OPHTHALMOLOGY
- Bevacizumab-induced hypertension: Clinical presentation and molecular understanding
- (2018) Megan Li et al. PHARMACOLOGY & THERAPEUTICS
- Overview of Systematic Reviews and Meta-analyses on Systemic Adverse Events Associated With Intravitreal Anti–Vascular Endothelial Growth Factor Medication Use
- (2018) Marie Thulliez et al. JAMA Ophthalmology
- Risk of Systemic Adverse Events Associated with Intravitreal Anti–VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice
- (2018) Maya H. Maloney et al. OPHTHALMOLOGY
- Prediction of risk of diabetic retinopathy for all-cause mortality, stroke and heart failure
- (2017) Xiao-Rong Zhu et al. MEDICINE
- SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB
- (2017) Robert L. Avery et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration
- (2017) Joel Hanhart et al. BMC Ophthalmology
- Vascular Safety of Ranibizumab in Patients With Diabetic Macular Edema
- (2017) Marco A. Zarbin et al. JAMA Ophthalmology
- Integration of pro- and anti-angiogenic signals by endothelial cells
- (2017) Shideh Kazerounian et al. Journal of Cell Communication and Signaling
- Increased Burden of Cerebral Small Vessel Disease in Patients With Type 2 Diabetes and Retinopathy
- (2016) Jordi Sanahuja et al. DIABETES CARE
- Intravitreal Aflibercept for Diabetic Macular Edema
- (2016) Jeffrey S. Heier et al. OPHTHALMOLOGY
- Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory
- (2016) Pedro Romero-Aroca et al. Journal of Diabetes Research
- Systemic Safety of Prolonged Monthly Anti–Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema
- (2016) Robert L. Avery et al. JAMA Ophthalmology
- Designed Ankyrin Repeat Proteins (DARPins): Binding Proteins for Research, Diagnostics, and Therapy
- (2015) Andreas Plückthun Annual Review of Pharmacology and Toxicology
- Pharmacokinetic and Pharmacodynamic Properties of Anti-VEGF Drugs After Intravitreal Injection
- (2015) Francesco Semeraro et al. CURRENT DRUG METABOLISM
- Myofibroblasts in proliferative diabetic retinopathy can originate from infiltrating fibrocytes and through endothelial-to-mesenchymal transition (EndoMT)
- (2015) Ahmed M. Abu El-Asrar et al. EXPERIMENTAL EYE RESEARCH
- Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy
- (2015) et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Neuropilin 1 (NRP1) hypomorphism combined with defective VEGF-A binding reveals novel roles for NRP1 in developmental and pathological angiogenesis
- (2014) A. Fantin et al. DEVELOPMENT
- Three-Year Outcomes of Individualized Ranibizumab Treatment in Patients with Diabetic Macular Edema
- (2014) Ursula Schmidt-Erfurth et al. OPHTHALMOLOGY
- Safety and Efficacy of Conbercept in Neovascular Age-Related Macular Degeneration
- (2014) Xiaoxin Li et al. OPHTHALMOLOGY
- Systemic Vascular Safety of Ranibizumab for Age-Related Macular Degeneration
- (2014) Takashi Ueta et al. OPHTHALMOLOGY
- Control of Angiogenesis by Galectins Involves the Release of Platelet-Derived Proangiogenic Factors
- (2014) Julia Etulain et al. PLoS One
- Cardiovascular Events and Bleeding Risk Associated With Intravitreal Antivascular Endothelial Growth Factor Monoclonal Antibodies
- (2014) Marie Thulliez et al. JAMA Ophthalmology
- VEGF-A165b Is an Endogenous Neuroprotective Splice Isoform of Vascular Endothelial Growth Factor A in Vivo and in Vitro
- (2013) Nicholas Beazley-Long et al. AMERICAN JOURNAL OF PATHOLOGY
- Bevacizumab vs ranibizumab—an appraisal of the evidence from CATT and IVAN
- (2013) F G Ahfat et al. EYE
- eNOS-derived nitric oxide regulates endothelial barrier function through VE-cadherin and Rho GTPases
- (2013) Annarita Di Lorenzo et al. JOURNAL OF CELL SCIENCE
- Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials
- (2013) David M. Brown et al. OPHTHALMOLOGY
- Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives
- (2013) Rafael Simó et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- A 2-Year Prospective Randomized Controlled Trial of Intravitreal Bevacizumab or Laser Therapy (BOLT) in the Management of Diabetic Macular Edema
- (2012) Ranjan Rajendram et al. ARCHIVES OF OPHTHALMOLOGY
- The vascular endothelial growth factor (VEGF)-E encoded by orf virus regulates keratinocyte proliferation and migration and promotes epidermal regeneration
- (2012) Lyn M. Wise et al. CELLULAR MICROBIOLOGY
- Effect of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy on the Risk of Arterial Thromboembolic Events: A Meta-Analysis
- (2012) Jin-Wei Cheng et al. PLoS One
- Hospitalized cardiovascular events in patients with diabetic macular edema
- (2012) Bao-Anh Nguyen-Khoa et al. BMC Ophthalmology
- Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab
- (2010) K. Matsuyama et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Snake Venom Vascular Endothelial Growth Factors (VEGF-Fs) Exclusively Vary Their Structures and Functions among Species
- (2009) Yasuo Yamazaki et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The basics of epithelial-mesenchymal transition
- (2009) Raghu Kalluri et al. JOURNAL OF CLINICAL INVESTIGATION
- Retinopathy predicts coronary heart disease mortality
- (2008) G Liew et al. HEART
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More